Kopran's Evaluation Score Adjusted Amid Mixed Performance and Debt Management Strength

Kopran, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation score. This revision reflects a shift in technical trends, moving from a bearish outlook to a mildly bearish stance.
The stock's performance indicators reveal a mixed picture. Over the past year, Kopran has generated a return of -29.72%, significantly lagging behind the BSE500 index. In the last three years, the stock has also underperformed, with a return of -10.12% compared to the index's 53.99%. Despite these challenges, the company maintains a low Debt to EBITDA ratio of 1.00 times, indicating a strong ability to service its debt obligations.

Financial metrics show that net sales have grown at an annual rate of 11.86% over the past five years, while operating profit has increased at a rate of 10.94%. However, the company has reported negative results for the last three consecutive quarters, with a decline in profit after tax and profit before tax.

Kopran's current price stands at 179.50, with a 52-week high of 369.20 and a low of 157.00. The stock's valuation appears attractive when compared to its peers, trading at a discount relative to average historical valuations.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.